Idarubicine
KIT Gene Mutation
The First Affiliated Hospital of Soochow UniversityPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the KIT Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 1/2 | CC |
Avapritinib The First Affiliated Hospital of Soochow University | Phase 1/2 | CC |
Azacitidine The First Affiliated Hospital of Soochow University | Phase 1/2 | CC |
Venetoclax The First Affiliated Hospital of Soochow University | Phase 1/2 | CC |
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →